^{Glossary: ABC: Advanced breast cancer; AI: Aromatase inhibitor; ARID1A: AT-rich interactive domain-containing protein 1A; CBR: Clinical benefit rate; CCND1: Cyclin D1; CDK4/6i: Cyclin-dependent kinase 4/6 inhibitor; CI: Confidence interval; ctDNA: Circulating tumor deoxyriboneucleic acid; ECOG: Eastern Cooperation Oncology Group; ESR1: Estrogen receptor 1; ET: Endocrine therapy; FGFR 1/2: Fibroblast growth factor receptor 1/2; HER2-: Human epidermal growth factor receptor 2-negative; HR: Hazard ratio; HR+: Hormone receptor-positive; IM: Intramuscular; MAP3K1: Mitogen-activated protein kinase kinase kinase 1; MAPK: Mitogen activated protein kinase; N/A: Not applicable; ORR: Overall response rate; OS: Overall survival; PFS: Progrssion-free survival; PIK3CA: Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; PI3K: Phosphatidylinositol 3-kinase; PO: Oral; PS: Performance status; QD: Once daily; QoL: Quality of life; TMB: Tumor mutational burden; TP53: Tomor protein 53}